Stay updated on CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial
Sign up to get notified when there's something new on the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page.

Latest updates to the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page
- Check7 days agoChange DetectedRevision metadata updated: added Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check36 days agoChange DetectedThe page now shows Revision: v3.5.0, replacing Revision: v3.4.3.SummaryDifference0.0%

- Check43 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This appears to be a system-level update with no visible changes to the study details on the page.SummaryDifference0.0%

- Check71 days agoChange DetectedAn administrative revision tag (v3.4.2) was added and previously displayed notices about government funding and operating status were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check78 days agoChange DetectedAdded a government funding lapse notice banner. Updated the page revision tag from v3.4.0 to v3.4.1.SummaryDifference0.3%

- Check85 days agoChange DetectedA glossary display option has been added. Labels related to QC status and FEAR Act data were capitalized (Last Update Submitted that Met QC Criteria; No FEAR Act Data) and the revision version updated to v3.4.0.SummaryDifference0.2%

Stay in the know with updates to CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page.